DBV Technologies SA. Daily Stock Analysis

Daily Stock Analysis, DBVT, DBV Technologies SA, priceseries

DBV Technologies SA. Daily Stock Analysis
Stock Information
Open
1.24
Close
1.22
High
1.28
Low
1.21
Previous Close
1.34
Daily Price Gain
-0.12
YTD High
1.86
YTD High Date
Jan 4, 2022
YTD Low
1.21
YTD Low Date
Mar 7, 2022
YTD Price Change
-0.55
YTD Gain
-31.07%
52 Week High
6.88
52 Week High Date
Apr 30, 2021
52 Week Low
1.21
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-4.03
52 Week Gain
-76.76%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jul 6. 2017
36.00
Aug 8. 2017
44.75
23 Trading Days
24.32%
Link
LONG
Dec 15. 2017
21.93
Jan 16. 2018
25.57
19 Trading Days
16.62%
Link
LONG
Aug 17. 2018
18.80
Sep 5. 2018
21.16
12 Trading Days
12.55%
Link
LONG
Sep 7. 2018
21.88
Sep 26. 2018
23.76
13 Trading Days
8.57%
Link
LONG
Apr 3. 2019
7.84
Apr 18. 2019
8.72
11 Trading Days
11.20%
Link
LONG
Apr 23. 2019
9.10
May 7. 2019
9.59
10 Trading Days
5.41%
Link
LONG
Jul 1. 2019
8.67
Jul 16. 2019
10.08
10 Trading Days
16.22%
Link
LONG
Dec 11. 2019
8.09
Jan 22. 2020
12.11
27 Trading Days
49.67%
Link
LONG
Apr 17. 2020
4.48
May 4. 2020
5.39
11 Trading Days
20.30%
Link
LONG
Jun 2. 2020
4.95
Jun 11. 2020
5.21
7 Trading Days
5.25%
Link
LONG
Nov 3. 2020
2.06
Nov 18. 2020
2.33
11 Trading Days
13.14%
Link
LONG
Jan 12. 2021
3.70
Jan 27. 2021
5.43
10 Trading Days
46.86%
Link
LONG
Apr 6. 2021
5.47
Apr 20. 2021
5.93
10 Trading Days
8.41%
Link
Company Information
Stock Symbol
DBVT
Exchange
NasdaqGS
Company URL
http://www.dbv-technologies.com
Company Phone
33(0)155427878
CEO
Pierre-Henri Benhamou
Headquarters
-
Business Address
177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE, FRANCE 92120
Sector
Equity
Industry Category
Drugs
Industry Group
Diagnostic Substances
CIK
0001613780
About

DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products. The company focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient, self-administered, non-invasive immunotherapy to patients. It has designed two products candidates: Viaskin Peanut and Viaskin Milk. DBV Technologies was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Description

DBV Technologies S.A. is engaged in the research, development, and marketing of products for the diagnosis and treatment of allergies, primarily food allergies in young children. The company provides Diallertest, a non-invasive patch allergy diagnostic for infants, children, or adults for the diagnosis of allergy in cow milk, wheat, and soybean. Its products include Viaskin Peanut, an immunotherapy product for the treatment of patients with peanut allergies; Viaskin Milk, for the treatment of CMPA and eosinophilic esophagitis, as well as food polyallergies; and Viaskin House Dust Mite, a mite desensitization product for the treatment of mite allergy. The company was founded in 2002 and is based in Bagneux, France.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading